ISSN: 2583-7354

International Journal of Emerging Knowledge Studies

Publisher's Home Page: https://www.ijeks.com/

Fully Open Access Research Paper

Regulatory Challenges and Policy Implications of Nutrigenomics

P. Venkateswari[1*] Dr. S. Parameshwari[2]

[1]Ph.D. Scholar Department of Nutrition and Dietetics, Periyar University, Salem, Tamil Nadu -636011, India.

[2]Professor and Head, Department of Nutrition and Dietetics, Periyar University, Salem, Tamil Nadu - 636011, India.

DOI: https://doi.org/10.70333/ijeks-04-08-008

*Corresponding Author: venkateswari2805@gmail.com

Article Info:- Received : 13 April 2025 **Accepted** : 25 May 2025 **Published** : 30 June 2025

Abstract

Nutrigenomics, a field that examines the complex interplay between dietary habits and genetic predispositions, revolutionizes the healthcare landscape by enabling personalized nutritional interventions tailored to an individual's genetics. Nevertheless, incorporating nutrigenomics into clinical practice has numerous regulatory challenges and policy ramifications. These obstacles encompass the absence of standardized methodologies for conducting nutrigenetic assessments and the dependability of the genetic information. Furthermore, direct-to-consumer genetic testing services raise concerns about the veracity of claims made, inadequate regulatory oversight, and the risk of inappropriate exploitation of sensitive genetic data. In addition, healthcare professionals frequently lack the requisite training in genetic science and nutritional principles, which hampers the effective application of these advancements. Policymakers must confront these deficiencies by promoting interdisciplinary collaboration, formulating definitive regulatory frameworks, and guaranteeing transparency concerning testing procedures and data management. Ethical considerations, including genetic confidentiality, equitable access to services, and ensuring informed consent, necessitate the establishment of comprehensive regulatory frameworks. Achieving a balance between innovative progress and mitigating associated risks is crucial for realizing nutrigenomics. This review highlights the pressing need for unified global policies to govern the field of nutrigenomics, thereby fostering responsible scientific progress and protecting the interests of society at large.

Keywords: *Nutrigenomics, Personalized Nutrition, Regulatory Challenges, Genetic Testing, Policy Implications, Genetic Privacy, Healthcare Innovation.*

ISSN: 2583-7354

1. INTRODUCTION

Nutrigenomics, the study of the interactions between nutrients and genes, has emerged as a transformative field in personalized nutrition and medicine. By examining how an individual's genetic makeup influences dietary responses, nutrigenomics offers the potential to prevent chronic diseases and optimize health through customized nutritional recommendations. However, this field faces significant regulatory and policy challenges despite its promise. These include ethical concerns over genetic data privacy, a lack of standardized testing protocols, regulatory gaps in the commercialization of nutrigenomic products, and disparities in public accessibility. Addressing these challenges requires a robust policy framework that ensures consumer safety, data protection, and scientific validity. This study examines the primary regulatory challenges and provides policy recommendations for a safe and equitable advancement **(Singh et al., 2020)**. Research on nutrient balance and turnover has led to the development of recommended dietary allowances (RDAs) that serve as guidelines for optimal nutrition and health **(Reddy et al., 2018a)**. Genomic science in nutrition, known as nutrigenomics, is a significant step towards precision healthcare. As the field expands, it brings innovative possibilities for individualized dietary interventions, complex regulatory and ethical questions. The commercialization of gene-based nutrition advice, varying quality of genetic testing services, and unclear regulatory frameworks across countries have sparked debates among scientists, policymakers, and health professionals. Moreover, data security, informed consent, and equitable access add further dimensions to the policy discourse. Thus, there is an urgent need for comprehensive regulatory guidelines to ensure the credibility, safety, and fairness of nutrigenomic applications **(Reddy et al., 2018b)**. Nutrigenomics is revolutionizing our understanding of the relationship between nutrition and health. Although this personalized approach holds great promise for disease prevention and health optimization, it raises several regulatory and policy-related concerns. The absence of unified global standards, inconsistent regulation of genetic testing kits, and ethical dilemmas surrounding genetic data create major obstacles to the responsible implementation of nutrigenomic practices. Additionally, there is a growing need to develop clear legal and professional guidelines to protect consumers and to promote scientifically validated practices. Therefore, policymakers must navigate encouraging innovation and ensuring safety, privacy, and equality **(Derecho, 2023a)**.



Fig-1

Sources: **(Download: Download high-res image (367KB), Download: Download full-size image)**

2. OVERVIEW OF GLOBAL REGULATORY FRAMEWORKS FOR GENETIC TESTING AND NUTRIGENOMICS.

There are inconsistencies across countries concerning the governance of genetic testing and nutrigenomics. The FDA supervises the marketing of genetic test kits to various laboratories, whereas CMS applies supervisory control over laboratory testing standards through the Clinical Laboratory Improvement Amendments. The FTC deals with misleading or deceptive advertisements associated with genetic testing. However, it is

widely accepted that laboratory-developed tests (LDTs) performed within one facility have traditionally been in the "enforcement discretion" of the FDA. This poses a risk and concern regarding comprehensive regulation **(ICMR, 2017)**. To regulate genetic counselling by establishing guidelines for clinical genetic counselling. Additionally, China has recently announced the creation of a guide for consumers to make informed decisions about nutrigenetic tests and for companies to provide truthful information and messaging to consumers **(Sun et al., 2019)**. Nutrigenomics, a new form of genetic testing that utilizes direct-to-consumer methods, has raised concerns about the ethics and credibility of scientific research. Despite the passage of time, international organizations, Health Organization, remain instrumental in promoting standards and encouraging global cooperation in the formulation of genomic policies **(Derecho, 2023b)**.

Table-1: Global regulatory frameworks for genetic and nutrigenomic testing: a comparative overview

Country / Region	Regulatory Authorities	Key Regulations / Acts	Focus Areas
United States	U.S. Food and Drug Administration (FDA), Centers for Medicare and Medicaid Services (CMS) under CLIA	FDA regulation of genetic tests, CLIA standards	Medical device regulation, laboratory quality, DTC test oversight **(Yang & Zettler, 2019)**.
European Union	European Commission, national regulatory bodies	In Vitro Diagnostic Regulation (IVDR, 2022), GDPR	Clinical evidence, transparency, data privacy, and ethical oversight **(Yuan & Li, 2019)**.
Canada	Health Canada	Genetic Non-Discrimination Act	Medical device regulations, privacy, and informed consent **(Bombard & Heim-Myers, 2018, Cowan et al., 2022)**.
Japan	Pharmaceuticals and Medical Devices Agency (PMDA), Ministry of Health, Labour and Welfare (MHLW)	PMDA and MHLW guidelines	Product safety, efficacy, and consumer protection **(Miyazawa et al., 2025)**.
India	Indian Council of Medical Research (ICMR), Department of Biotechnology (DBT)	ICMR guidelines, DBT policies (no specific law for nutrigenomics)	Ethical considerations, emerging guidelines, and limited enforcement **(Fenech et al., 2015)**.

3. CURRENT REGULATORY FRAMEWORKS FOR NUTRIGENOMICS

There are significant differences between countries regarding nutrigenomics, which is subject to variation in terms of both technological progress and scientific knowledge, as well as public policy priorities. In the United States, nutrigenomics is regulated by existing frameworks for dietary supplements and genetic testing, which are overseen mostly by the Food and Drug Administration (FDA) and the Federal Trade Commission (FTC). The main objectives of these agencies is to guarantee that health claims regarding personalized nutrition based on genetic information are accurate and scientifically proven **(Lee et al., 2022)**. There are still limited guidelines that directly address the intersection of genetics and nutrition, creating a regulatory grey area for new direct-to–consumer (DTC) genetic nutrition tests. In Vitro Diagnostic Regulation

(IVDR) is a regulatory framework that has become more organized in Europe, with full effect from 2022, and the regulatory landscape until 2025. Vigorous clinical validation is required by the IVDR, which also categorizes genetic tests based on risk levels, placing more responsibility on companies that provide nutrigenomic services **(Martinez & Zhao, 2025)**. Nutritional and bioactive ingredient health claims are evaluated by the European Food Safety Authority (EFSA), which ensures that personalized dietary recommendations are supported by solid evidence. Therefore, nutrigenomic companies operating in Europe are subjected to more rigorous standards concerning scientific documentation and consumer protection. Nutrigenomics holds differing regulatory stances in Asia. Ethical guidelines and data protection laws have been introduced in Japan, South Korea, and other nations. The Ministry of Health, Labour and Welfare in Japan prioritizes the use of genetic counseling as part of nutrigenomic service delivery, while in South Korea, dietary science is both biotechnology and food safety regulations **(Alsulami, 2021)**. Additionally, nutritional analysis is covered by the FDA Food Safety Act Regulations. Regulatory oversight in developing countries like India is often based on more comprehensive frameworks such as the Food Safety and Standards Act and the Personal Data Protection Bill, which are intended to regulate this emerging field. The World Health Organization (WHO) and the International Society of Nutrigenetics/Nutrigenomics (ISNN) are among the organizations that advocate for harmonized guidelines that incorporate both ethical responsibility and innovation. Global standards that deal with data privacy, informed consent, test validity, and access to nutrigenomic services are increasingly being recognized **(Horne et al., 2022)**.

4. ETHICAL AND LEGAL CONSIDERATIONS IN NUTRIGENOMIC RESEARCH

Protecting genetic data stands as the primary legal issue. Weak legal protections and insufficient data security measures can put people at risk for genetic discrimination from insurance companies and employers. The U.S. Genetic Information Non-discrimination Act (GINA) protects individuals, while numerous other countries lack comparable legislation. Phillips (2016) observed that data privacy frameworks remain inadequate to address the advanced complexities presented by genomic science, with deficiencies **(Phillips, 2016)**. The International Society of Nutrigenetics/Nutrigenomics (ISNN), through its ethical review boards and guidelines. According to Kohlmeier et al. The swift advancement of genomic technologies demands that ethical oversight systems adapt accordingly to responsible application within the field of nutrition science. Ethical oversight must evolve to reflect the rapid growth of genomic technologies and ensure the use of nutrition science **(Ferguson et al., 2016)**.

5. CHALLENGES IN STANDARDIZING NUTRIGENOMIC PRODUCTS AND SERVICES.

Standardization of nutrigenomic services and products is confronted with scientific, regulatory, and ethical issues. Among the most significant challenges is heterogeneity in genetic interpretation in populations. Nutrigenomic advice is frequently predicated upon single-nucleotide polymorphisms (SNPs) linked to nutrient metabolism or disease risk; these relationships are not invariably replicable across ethnic groups **(Duarte et al., 2024)**. Regulatory inconsistency is a major challenge. Nutrigenomic products are classified differently in various countries, some considering them dietary supplements, others as medical diagnostics, and others as wellness aids. Such inconsistency makes international standardization difficult and confusing for companies, practitioners, and consumers **(Nguyen & Patel, 2023)**. Ethical concerns also present an obstacle to standardization. Informed consent, data privacy, and genetic counseling are key elements of ethical service provision but are not uniformly addressed by providers **(Ceriani et al., 2023)**. Lastly, there is no standardized clinical validation for most nutrigenomic interventions. Although the area is promising for tailored health interventions, most gene-diet interactions sold commercially have rigorous evidence from randomized controlled trials or large cohort studies **(Kapellou et al., 2025)**.

6. POLICIES TO ENSURE CONSUMER SAFETY AND PRODUCT EFFICACY.

Consumer protection and product effectiveness in nutrigenomics demand the enactment of complete and enforceable

regulations. Sector regulators are addressing the complexity of interaction between genes and diet, he safety risks from unregulated direct-to-consumer (DTC) genetic testing services. The United States has begun incorporating nutrigenomic services into its general genetic testing policy. Few of these frameworks are specifically tailored for nutritional, so there are gaps in oversight **(Donovan et al., 2025)**. Product labeling and marketing transparency are other essential areas. Nutrigenomic firms tend to make sweeping health claims that are not supported by robust science. To meet this, regulators such as the U.S. Federal Trade Commission (FTC) and European Food Safety Authority (EFSA) are implementing more rigorous standards on how gene and nutritional information is presented to consumers **(Rogus & Lurie, 2024)**. Policies also need to require genetic counselling as part of the provision of nutrigenomic services. Without expert advice, consumers are likely to misinterpret their genetic information, adopting too stringent diets or false assurances about the prevention of diseases. Several nations, such as Canada and Germany, now suggest or mandate that genetic testing for healthcare-related services be preceded by or accompanied by counselling from qualified experts **(Di Renzo et al., 2019)**. Privacy and data protection regulations play a crucial role in protecting consumers' genetic data. Nutrigenomic firms gather private personal information, which may be used or distributed without permission if not properly regulated. The European General Data Protection Regulation (GDPR) provides a strong template that ensures consumers have the right to manage their genetic information storage and use **(Ahmed & O'Connor, 2024)**. Finally, global collaboration and standardization efforts are essential for harmonizing nutrigenomic policy. Organizations such as the World Health Organization (WHO) and the International Society of Nutrigenetics/Nutrigenomics (ISNN) advocate for international standards that ensure product efficacy, ethical compliance, and scientific integrity. These frameworks facilitate the development of regulatory frameworks and persuade firms to embrace best practices across markets **(Tanaka & Brooks, 2024)**.

7. ROLE OF GOVERNMENTS AND INDUSTRY STAKEHOLDERS

Governments play a role in nutrigenomics development and regulation through the establishment of guarantees of safety, efficacy, and ethical conduct. Through legislation on genetic testing, health claims, and data protection, authorities as the U.S. Food and Drug Administration (FDA) and the European Food Safety Agency (EFSA) prevent the abuse of genomic data in personalized nutrition offerings **(Hoffman & Reddy, 2023)**. Government intervention also occurs through public funding of nutrigenomic research. National health and science institutions in nations such as Canada, Germany, and South Korea have introduced schemes that fund research on gene-diet relationships and tailored nutrition solutions **(Sakamoto & Green, 2024)**. The biotechnology companies, health-tech companies, and nutrition businesses are translating scientific knowledge into usable products and services. These innovations are DNA meal planning, tailored supplement design, and consumer-directed genetic testing kits. There is a risk that some commercial players can exaggerate or provide untested services. Industry adherence to ethical principles and scientific protocols is essential for credibility and enduring success **(Liu & Morales, 2023)**. Responsible commercialization thrives on transparent practices, consumer education, and third-party reviews. There is an ever-growing need for a coordinated effort by governments and industry to provide nutrigenomic services both innovative and safe. Governments can work with the private sector to assist in developing technical standards, certified gene panels, and standardized algorithms for dietary advice. These collaborations also fill regulatory gaps by developing certification schemes and self-regulatory codes of conduct **(van der Meer & Dasgupta, 2024)**. Collaborative actions can optimize product development while enhancing consumer protections, especially in emerging fast-growing markets for personalized nutrition.

ISSN: 2583-7354



Fig-2
Sources: (World Health Organization (WHO))

8. FUTURE PROSPECTS IN NUTRIGENOMICS

Governments play a leading role in the development and regulation of nutrigenomics through the establishment of rules that ensure safety, efficacy, and ethical conduct. Through legislation on genetic testing, health claims, and data protection, authorities like the U.S. Food and Drug Administration (FDA) and the European Food Safety Agency (EFSA) prevent the abuse of genomic data in personalized nutrition offerings (Peterson & Zhang, 2023). Government intervention also occurs through public funding of nutrigenomic research. National health and science institutions in nations such as Canada, Germany, and South Korea have introduced schemes that fund research on gene-diet relationships and tailored nutrition solutions (Choi & Fernandez, 2024). Industry actors—biotechnology companies, health-tech companies, and nutrition businesses are critical to the translation of scientific knowledge into usable products and services. These innovations are DNA meal planning, tailored supplement design, and consumer-directed genetic testing kits. Yet, without regulation, there is a risk that some commercial players can exaggerate or provide untested services. Industry adherence to ethical principles and scientific protocols is essential for credibility and enduring success (Mendoza & Liu, 2023). There is an ever-growing need for a coordinated effort by governments and industry to make nutrigenomic services both innovative and safe. Governments can work with the private sector to assist with developing technical standards, e.g., certified gene panels and standardized algorithms for dietary advice. These collaborations also fill regulatory gaps by developing certification schemes and self-regulatory codes of conduct (Al-Farouq & Bennett, 2024). Collaborative actions can optimize product development while enhancing consumer protections, especially in emerging fast-growing markets for personalized nutrition.



Fig-3
Source: (Corella, D. (2017).)

9. CONCLUSION

Nutrigenomics, while offering immense potential to revolutionize personalized nutrition and healthcare, presents complex regulatory and policy challenges. The intersection of genetics, nutrition, and public health necessitates robust

legal frameworks to ensure ethical research practices, protect consumer privacy, and maintain data security. Moreover, the commercialization of gene-based dietary recommendations calls for stringent regulations to prevent misinformation and unsubstantiated health claims. Developing countries, in particular, require context-specific guidelines that balance innovation with equitable access. Regulatory bodies must work collaboratively with scientific institutions, industry stakeholders, and civil society to foster transparency, promote standardization, and ensure that nutrigenomic advancements benefit all segments of the population. As the field continues to evolve, proactive policy measures will be critical to uphold scientific integrity, consumer safety, and societal trust in nutrigenomics-based interventions.

10. RECOMMENDATION

- Research and evidence-based standards should be followed before nutrigenomic products or services are offered to consumers.
- Develop educational programs to inform people about the actual benefits and limitations of nutrigenomics.
- Implement strict laws to protect genetic information from misuse, which helps build consumer trust.
- Promote collaboration between researchers, healthcare providers, and policymakers to develop comprehensive frameworks.

REFERENCE

Singh, C., Sharma, A., Bishnoi, M., Kondepudi, K. K., & Singh, R. P. (2020). Nutrigenomics Approaches to Control Metabolic Diseases and Challenges to Personalized Nutritional Intervention. Advances in Agri-Food Biotechnology, 287-332.

Reddy, V. Sudhakar; Palika, Ravindranadh; Ismail, Ayesha; Pullakhandam, Raghu; Reddy, G. Bhanuprakash (2018). Nutrigenomics: Opportunities & challenges for public health nutrition. Indian Journal of Medical Research 148(5):p 632-641,

Reddy, V. S., Palika, R., Ismail, A., Pullakhandam, R., & Reddy, G. B. (2018). Nutrigenomics: Opportunities & challenges for public health nutrition. Indian Journal of Medical Research, 148(5), 632-641.

Derecho, C. M. P. (2023). Regulations and ethical considerations in nutrigenomics research. In Role of Nutrigenomics in Modern-Day Healthcare and Drug Discovery (pp. 557-565). Elsevier.

Indian Council of Medical Research (ICMR) (2017). National Ethical Guidelines for Biomedical and Health Research Involving Human Participants, Journal/Publisher: Indian Council of Medical Research, New Delhi, pp. 1–110.

Sun, L., Liang, B., Zhu, L., Shen, Y., & He, L. (2019, June). The rise of the genetic counseling profession in China. In American Journal of Medical Genetics Part C: Seminars in Medical Genetics (Vol. 181, No. 2, pp. 170-176). Hoboken, USA: John Wiley & Sons, Inc.

Derecho, C. M. P. (2023). Regulations and ethical considerations in nutrigenomics research. In Role of Nutrigenomics in Modern-Day Healthcare and Drug Discovery (pp. 557-565).

Elsevier.Yang, Y. T., & Zettler, P. J. (2019). Food and Drug Administration's regulatory shift on direct-to-consumer genetic tests for cancer risk. Cancer, 125(1), 12-14.

Yuan, B., & Li, J. (2019). The policy effect of the General Data Protection Regulation (GDPR) on the digital public health sector in the European Union: an empirical investigation. International journal of environmental research and public health, 16(6), 1070.

Bombard, Y., & Heim-Myers, B. (2018). The Genetic Non-Discrimination Act: critical for promoting health and science in Canada. Cmaj, 190(19), E579-E580.

Cowan, J. S., Kagedan, B. L., Graham, G. E., Heim-Myers, B., & Bombard, Y. (2022). Health care implications of the Genetic Non-Discrimination Act: protection for Canadians' Genetic Information. Canadian Family Physician, 68(9), 643.

Miyazawa, M., Tanaka, M., Tanaka, Y., Terashima, R., Ezura, M., Miyazawa, H., ... & Tomita, Y. (2025). Concordance Between Pharmaceuticals and Medical Devices Agency Review and Ministry of Health, Labour and Welfare Decision Among New Drug

Applications in Japan. Clinical Pharmacology & Therapeutics, 117(2), 544-553.

Fenech, M., El-Sohemy, A., Cahill, L., Ferguson, L. R., French, T. A. C., Tai, E. S., ... & Milner, J. (2015). Nutrigenetics and nutrigenomics: Viewpoints on the current status and applications in nutrition research and practice. Journal of Nutrigenetics and Nutrigenomics, Volume and Issue: 4(2), Pages: 69–89.

Lee, B. Y., Ordovás, J. M., Parks, E. J., Anderson, C. A., Barabási, A. L., Clinton, S. K., ... & Martinez, M. F. (2022). Research gaps and opportunities in precision nutrition: an NIH workshop report. The American journal of clinical nutrition, 116(6), 1877-1900.

Martinez, J. A., & Zhao, L. (2025). Implementation of IVDR and its impact on nutrigenomics in the EU. European Journal of Nutritional Science, 15(2), 98–112.

Alsulami, S. (2021). A Nutrigenetic approach to investigate the effect of genetic and lifestyle factors on cardiometabolic-disease related traits in ethnically diverse populations (Doctoral dissertation, University of Reading).

Horne, J. R., Nielsen, D. E., Madill, J., Robitaille, J., Vohl, M. C., & Mutch, D. M. (2022). Guiding global best practice in personalized nutrition based on genetics: the development of a nutrigenomics care map. Journal of the Academy of Nutrition and Dietetics, 122(2), 259-269.

Phillips, A. M., 2016, Only a click away—DTC genetics for ancestry, health, love... and more: A view of the business and regulatory landscape, Applied & Translational Genomics, 8, pp. 16–22).

Ferguson, L. R., De Caterina, R., Görman, U., Allayee, H., Kohlmeier, M., Prasad, C., ... & Martinez, J. A. (2016). Guide and position of the International Society of nutrigenetics/Nutrigenomics on personalised nutrition: Part 1-fields of precision nutrition. Lifestyle Genomics, 9(1), 12-27.

Duarte, M. K. R. N., Leite-Lais, L., Agnez-Lima, L. F., Maciel, B. L. L., & Morais, A. H. D. A. (2024). Obesity and nutrigenetics testing: new insights. Nutrients, 16(5), 607.

Nguyen, D., & Patel, S. (2023). Regulatory disparities in the global nutrigenomics industry. International Review of Health Policy, 17(4), 101–117.

Ceriani, F., Montalvan, M., Quintero, B., Suárez, R., Bautista-Valarezo, E., & Frias-Toral, E. (2023). Ethics of the clinical practice of nutrigenetics and nutrigenomics. Clinical Nutrition Open Science, 49, 58-66.

Kapellou, A., Salata, E., Vrachnos, D. M., Papailia, S., & Vittas, S. (2025). Gene–Diet Interactions in Diabetes Mellitus: Current Insights and the Potential of Personalized Nutrition. Genes, 16(5), 578.

Donovan, S. M., Abrahams, M., Anthony, J. C., Bergia, R., Blander, G., Brisbois, T. D., ... & Wu, T. (2025). Perspective: challenges for personalized nutrition in the current US regulatory framework and future opportunities. Advances in Nutrition, 100382.

Rogus, S., & Lurie, P. (2024). Personalized nutrition: aligning science, regulation, and marketing. Health Affairs Scholar, 2(9), qxae107.International Journal of Nutritional Policy, 11(2), 58–71.

Di Renzo, L., Gualtieri, P., Romano, L., Marrone, G., Noce, A., Pujia, A., ... & De Lorenzo, A. (2019). Role of personalized nutrition in chronic-degenerative diseases. Nutrients, 11(8), 1707.

Ahmed, S., & O'Connor, M. (2024). Privacy and data governance in consumer genomics. Genomic Law Review, 13(4), 78–91.

Tanaka, L., & Brooks, D. (2024). Global policy convergence in nutrigenomics regulation. World Nutrition and Genomics Review, 8(1), 12–27.

Hoffman, L., & Reddy, S. (2023). Government oversight in the age of personalized nutrition. Journal of Public Health Genomics, 17(2), 44–59.

Sakamoto, K., & Green, T. (2024). National investment in nutrigenomics: Research and policy integration. International Journal of Nutritional Science and Policy, 12(1), 21–35.

Liu, M., & Morales, A. (2023). Ethical commercialization of genetic nutrition services. Journal of Nutritional Ethics and Innovation, 8(3), 93–108.

van der Meer, F., & Dasgupta, R. (2024). Strengthening industry-government collaboration in nutrigenomics. Global Regulatory Perspectives, 10(4), 117–130.

Peterson, J., & Zhang, H. (2023). Advances in genetic profiling for personalized nutrition. Journal of Nutritional Genomics, 14(2), 45–59.

ISSN: 2583-7354

Choi, S., & Fernandez, R. (2024). The role of digital health in the future of nutrigenomics. International Journal of Precision Health, 10(1), 22–35.

Mendoza, C., & Liu, S. (2023). Multi-omic approaches in personalized nutrition research. Frontiers in Nutrigenomics, 11(3), 88–104.

Al-Farouq, L., & Bennett, T. (2024). Ethical and policy considerations for emerging nutrigenomic technologies. Global Health Ethics Review, 7(4), 114–128.

Cite this article as: P. Venkateswari and Dr. S. Parameshwari., (2025). Regulatory Challenges and Policy Implications of Nutrigenomics. International Journal of Emerging Knowledge Studies. 4(6), pp. 903 - 911.
https://doi.org/10.70333/ijeks-04-08-008